Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Nov;124(11S):S4-S13.
doi: 10.1016/j.ophtha.2017.07.010.

The Pathophysiology of Dry Eye Disease: What We Know and Future Directions for Research

Affiliations
Review

The Pathophysiology of Dry Eye Disease: What We Know and Future Directions for Research

Stephen C Pflugfelder et al. Ophthalmology. 2017 Nov.

Abstract

Clinical and laboratory studies performed over the past few decades have discovered that dry eye is a chronic inflammatory disease that can be initiated by numerous extrinsic or intrinsic factors that promote an unstable and hyperosmolar tear film. These changes in tear composition, in some cases combined with systemic factors, lead to an inflammatory cycle that causes ocular surface epithelial disease and neural stimulation. Acute desiccation activates stress signaling pathways in the ocular surface epithelium and resident immune cells. This triggers production of innate inflammatory mediators that stimulate the production of matrix metalloprotease, inflammatory cell recruitment, and dendritic cell maturation. These mediators, combined with exposure of autoantigens, can lead to an adaptive T cell-mediated response. Cornea barrier disruption develops by protease-mediated lysis of epithelial tight junctions, leading to accelerated cell death; desquamation; an irregular, poorly lubricated cornea surface; and exposure and sensitization of epithelial nociceptors. Conjunctival goblet cell dysfunction and death are promoted by the T helper 1 cytokine interferon gamma. These epithelial changes further destabilize the tear film, amplify inflammation, and create a vicious cycle. Cyclosporine and lifitegrast, the 2 US Food and Drug Administration-approved therapies, inhibit T-cell activation and cytokine production. Although these therapies represent a major advance in dry eye therapy, they are not effective in improving discomfort and corneal epithelial disease in all patients. Preclinical studies have identified other potential therapeutic targets, biomarkers, and strategies to bolster endogenous immunoregulatory pathways. These discoveries will, it is hoped, lead to further advances in diagnostic classification and treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Dry eye inflammatory cycle that can be initiated or amplified by extrinsic and intrinsic factors that cause tear instability and tear composition changes including hyperosmolarity that activate stress signaling pathways in the ocular surface cells which triggers production of innate inflammatory mediators which can lead to recruitment and activation of CD4+ T cells which produce cytokines that cause corneal, conjunctival and lacrimal gland epithelial disease.
Figure 2
Figure 2
Function of the cornea, conjunctival and lacrimal gland in maintaining ocular surface homeostasis (left side of each tissue) and disease relevant mediators and pathological changes in each tissue (right side of each tissue). IL-17 = interleukin 17, IL-13 = interleukin 13, IFN-γ = interferon-gamma

References

    1. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007) Ocul Surf. 2007;5(2):75–92. listed na. - PubMed
    1. Pflugfelder SC, de Paiva CS, Villarreal AL, Stern ME. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production. Cornea. 2008;27(1):64–9. - PubMed
    1. Pflugfelder SC, Stern ME. Mucosal environmental sensors in the pathogenesis of dry eye. Expert Rev Clin Immunol. 2014;10(9):1137–40. - PubMed
    1. Stern ME, Gao J, Schwalb TA, et al. Conjunctival T-cell subpopulations in Sjogren’s and non-Sjogren’s patients with dry eye. Invest Ophthalmol Vis Sci. 2002;43(8):2609–14. - PubMed
    1. Hingorani M, Metz D, Lightman SL. Characterisation of the normal conjunctival leukocyte population. Exp Eye Res. 1997;64(6):905–12. - PubMed

MeSH terms

Substances